Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
JUNEL FE 1/20 vs ALYACEN 1/35
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination of ethinyl estradiol and norethindrone suppresses gonadotropin-releasing hormone (Gn RH) from the hypothalamus, reducing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion from the pituitary, thereby inhibiting ovulation. Additionally, induces changes in cervical mucus and endometrium to impede sperm penetration and implantation.
Combination hormonal contraceptive: ethinyl estradiol suppresses gonadotropin release via negative feedback on hypothalamic-pituitary axis; norethindrone induces progestational effects including cervical mucus thickening and endometrial changes, inhibiting ovulation and sperm penetration.
Prevention of pregnancy,Treatment of moderate acne vulgaris (in females at least 15 years of age who have no known contraindications to oral contraceptive therapy and have achieved menarche),Management of menstrual disorders (off-label)
Prevention of pregnancy
One tablet orally once daily for 21 days, followed by 7 days of placebo tablets. Each active tablet contains 1 mg norethindrone acetate and 20 mcg ethinyl estradiol.
One tablet (norethindrone 1 mg and ethinyl estradiol 35 mcg) orally once daily for 21 consecutive days, followed by 7 days of placebo or no tablets.
Ethinyl estradiol: 13-27 hours (terminal); norethindrone: 5-14 hours (terminal). Clinically, steady-state is achieved within 5-6 days.
Norethindrone: 8-11 hours (terminal); ethinyl estradiol: 10-20 hours (terminal). The half-life supports once-daily dosing for oral contraceptive efficacy.
Ethinyl estradiol is primarily metabolized by CYP3A4; norethindrone is metabolized by reduction and conjugation (glucuronidation and sulfation).
Ethinyl estradiol: primarily hepatic via CYP3A4; norethindrone: hepatic reduction and sulfate conjugation.
Renal (primarily as metabolites; ~50-60% of dose), fecal (~30-40% of dose). Unchanged drug excretion is minimal.
Renal excretion of metabolites (primarily ethinyl estradiol and norethindrone conjugates) accounts for approximately 50-60% of elimination; fecal excretion accounts for 30-40%. Unchanged drug excretion is minimal (<5%).
Ethinyl estradiol: ~97% bound to albumin; norethindrone: ~61% bound to albumin and sex hormone-binding globulin (SHBG).
Norethindrone: 61% bound to albumin and SHBG; ethinyl estradiol: 97-98% bound to albumin.
Ethinyl estradiol: 2.0-4.0 L/kg; norethindrone: 3.0-4.5 L/kg. Indicates extensive tissue distribution.
Norethindrone: 3.8-4.5 L/kg; ethinyl estradiol: 2.0-4.0 L/kg. Large Vd indicates extensive tissue distribution.
Oral: Ethinyl estradiol ~45% (due to first-pass metabolism); norethindrone ~64%.
Oral: Norethindrone ~64%, ethinyl estradiol ~38-48% (due to first-pass metabolism).
No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (Cr Cl <30 m L/min); use contraindicated in patients with renal disease or renal impairment if it worsens or is associated with hyperkalemia.
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal impairment or acute renal failure due to potential fluid retention and electrolyte disturbances.
Contraindicated in patients with hepatic impairment (Child-Pugh class A, B, or C) or active liver disease. No dose adjustment applicable.
Contraindicated in patients with hepatic impairment, including Child-Pugh class B or C, due to impaired metabolism of estrogen and progestin. Not recommended in patients with active liver disease or history of liver tumors.
Safety and efficacy not established in pediatric patients. Not indicated for use before menarche.
Not indicated for use before menarche. For postmenarchal adolescents, same dosing as adults. Safety and efficacy established for contraception; weight-based dosing not applicable.
Not indicated for use in postmenopausal women. No specific geriatric dosing; contraindicated in women over 35 who smoke or have other risk factors.
Not indicated for use after menopause due to lack of benefit and increased risks (e.g., cardiovascular, thromboembolic events). If used, monitor for fluid retention, hypertension, and glucose intolerance.
Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptives. This risk increases with age (especially in women over 35 years) and with heavy smoking (≥15 cigarettes per day). Women who use combination hormonal contraceptives should be strongly advised not to smoke.
Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptives. Risk increases with age and heavy smoking (≥15 cigarettes/day). Women over 35 who smoke should not use this product.
Increased risk of thromboembolic disorders (e.g., venous thromboembolism, stroke, myocardial infarction),Hepatic neoplasia (benign and malignant),Gallbladder disease,Hypertension,Carbohydrate and lipid metabolic effects,Headache,Bleeding irregularities,Depression,Ocular lesions (e.g., retinal thrombosis),Carcinoma of the breast and reproductive organs,Use in pregnancy (discontinue if pregnancy occurs)
Thrombotic disorders (e.g., DVT, PE, stroke, MI),Cerebrovascular disease,Hepatic neoplasia,Gallbladder disease,Hypertension,Carbohydrate and lipid effects,Ocular lesions,Hereditary angioedema,Chloasma,Menstrual irregularities,Pregnancy exclusion prior to initiation
Thrombophlebitis, thromboembolic disorders, or history of these conditions,Cerebrovascular or coronary artery disease,Known or suspected breast cancer,Carcinoma of the endometrium or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma,Known or suspected pregnancy,Hypersensitivity to any component,Use with Hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, due to potential for ALT elevations
Venous or arterial thrombotic/thromboembolic disease (current or history),Cerebrovascular disease,Coronary artery disease,Known or suspected breast cancer,Endometrial or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma,Known or suspected pregnancy,Hypersensitivity to any component,Smoking in women over 35
No specific food restrictions. Grapefruit juice may theoretically increase estrogen levels but clinical significance is minimal; routine avoidance not required. Iron tablets (ferrous fumarate) may cause gastrointestinal upset; taking with food may reduce nausea. Avoid high-dose vitamin C supplements as they may increase estrogen absorption, but normal dietary intake is safe.
No significant food interactions. Grapefruit juice may increase estrogen levels, but clinically not a concern. Avoid excessive alcohol, which may impair liver function and increase estrogen exposure. Maintain a healthy diet, as weight gain is possible.
Pregnancy category X. Use is contraindicated during pregnancy due to risk of fetal harm. First trimester: Exposure is associated with cardiovascular defects and limb reduction defects. Second and third trimesters: Increased risk of fetal genital tract abnormalities (e.g., hypospadias, feminization of male fetuses).
Pregnancy category X. Use of ALYACEN 1/35 (norethindrone/ethinyl estradiol) is contraindicated during pregnancy. First trimester: Increased risk of congenital anomalies, including cardiovascular defects and limb reduction defects. Second/third trimesters: Potential for urogenital abnormalities and feminization of male fetus. Exposure is associated with subsequent development of clear cell adenocarcinoma of vagina/cervix in female offspring (DES-related).
Small amounts of ethinyl estradiol and norethindrone (the active components) are excreted into breast milk. The M/P ratio is approximately 0.1-0.3 for ethinyl estradiol and 0.5-1.0 for norethindrone. Use is generally not recommended during breastfeeding as it may reduce milk production and quality. If used, monitor infant for jaundice and growth.
Small amounts of contraceptive steroids and/or metabolites have been identified in breast milk. M/P ratio: Not specifically determined for this combination; ethinyl estradiol M/P ratio ~0.02-0.04. Use may reduce milk production and quality. Breastfeeding not recommended during use. Alternative contraception advised.
Contraindicated; no dose adjustment is indicated as the drug should be discontinued immediately upon pregnancy detection.
Contraindicated in pregnancy; no dose adjustments applicable. Discontinue medication immediately upon pregnancy detection.
Junel Fe 1/20 is a combined oral contraceptive (COC) containing ethinyl estradiol 20 mcg and norethindrone 1 mg. It is a low-dose pill; efficacy may be slightly lower than higher-dose pills. The iron supplement (ferrous fumarate) in the placebo pills is not intended for contraception; patients should not skip active pills. Missed pills increase risk of ovulation; if one active pill is missed, take it as soon as remembered and continue; if two or more are missed, use backup contraception for 7 days. Counsel on signs of venous thromboembolism (VTE): sudden leg pain, chest pain, shortness of breath. Consider alternatives in migraine with aura, uncontrolled hypertension, or smokers over 35. Drug interactions include rifampin, certain anticonvulsants (phenytoin, carbamazepine), and St. John's Wort which may reduce efficacy.
ALYACEN 1/35 is a combination oral contraceptive containing ethinyl estradiol 35 mcg and norgestimate 1 mg. It is indicated for the prevention of pregnancy and for the treatment of moderate acne vulgaris in females ≥15 years of age who desire an oral contraceptive. Monitor for thromboembolic events, especially in smokers over 35 or those with migraine with aura. Use with caution in patients with liver impairment or history of cholestatic jaundice. The pill-free interval should not exceed 7 days; missed pills increase ovulation risk. Consider non-hormonal backup if vomiting or diarrhea occurs within 4 hours of dosing.
Take one pill daily at the same time; the last 7 pills in each pack are iron tablets and do not provide contraception.,If you miss an active pill, take it as soon as you remember. If you miss two or more active pills, use a backup contraceptive method (e.g., condoms) for the next 7 days.,Vomiting or severe diarrhea within 4 hours of taking an active pill may reduce effectiveness; treat as a missed pill and consult your clinician.,Notify your clinician if you experience severe leg pain, chest pain, shortness of breath, severe headache, or vision changes.,Avoid smoking while on this medication, especially if over 35 years old, as it increases the risk of serious cardiovascular events.,Inform your clinician of all medications you take, including over-the-counter products and herbal supplements.
Take one tablet daily at the same time each day; do not skip doses.,Use an additional non-hormonal contraceptive (e.g., condoms) if you miss a pill, have vomiting, or diarrhea.,Smoking while on this pill increases the risk of blood clots and stroke, especially if you are over 35.,Contact your healthcare provider immediately if you have chest pain, leg pain/swelling, sudden vision changes, or severe headache.,This medication does not protect against HIV or other sexually transmitted infections.,Store at room temperature, away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about JUNEL FE 1/20 vs ALYACEN 1/35, answered by our medical review team.
JUNEL FE 1/20 is a Oral Contraceptive that works by Combination of ethinyl estradiol and norethindrone suppresses gonadotropin-releasing hormone (Gn RH) from the hypothalamus, reducing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion from the pituitary, thereby inhibiting ovulation. Additionally, induces changes in cervical mucus and endometrium to impede sperm penetration and implantation.. ALYACEN 1/35 is a Oral Contraceptive that works by Combination hormonal contraceptive: ethinyl estradiol suppresses gonadotropin release via negative feedback on hypothalamic-pituitary axis; norethindrone induces progestational effects including cervical mucus thickening and endometrial changes, inhibiting ovulation and sperm penetration.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between JUNEL FE 1/20 and ALYACEN 1/35 depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of JUNEL FE 1/20 is: One tablet orally once daily for 21 days, followed by 7 days of placebo tablets. Each active tablet contains 1 mg norethindrone acetate and 20 mcg ethinyl estradiol.. The standard adult dose of ALYACEN 1/35 is: One tablet (norethindrone 1 mg and ethinyl estradiol 35 mcg) orally once daily for 21 consecutive days, followed by 7 days of placebo or no tablets.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between JUNEL FE 1/20 and ALYACEN 1/35 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. JUNEL FE 1/20 is classified as Category C. Pregnancy category X. Use is contraindicated during pregnancy due to risk of fetal harm. First trimester: Exposure is associated with cardiovascular defects and limb reduction defe. ALYACEN 1/35 is classified as Category C. Pregnancy category X. Use of ALYACEN 1/35 (norethindrone/ethinyl estradiol) is contraindicated during pregnancy. First trimester: Increased risk of congenital anomalies, including . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.